Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00919620
Other study ID # jcep-rct
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2009
Est. completion date December 2015

Study information

Verified date November 2020
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

One of the commonly adopted strategies in improving outcome in psychotic disorders is by focused, specific and intensive intervention in the initial few years of the disorder. However the effects of intervention and the optimal duration of intervention have seldom been examined in randomized studies. This study uses a randomized controlled study design to investigate the effectiveness of stage-specific case-management in improving outcome of first episode psychotic disorders. It also addresses whether two years of case-management is less effective than four years of case-management over a four year period. A total of 360 subjects, who aged 25 above, and diagnosed with first episode psychotic disorders, will be and randomized into 3 groups: (1) standard care alone without case management, (2) two-year case management, (3) four-year case management. All groups will receive usual standard care treatment. This four-year follow-up study will assess symptoms, functioning, quality of life as well as health economics data.


Description:

Psychotic disorder is a debilitating illness which imposes substantial impact to the patients, their families, and the society. The provision of early intervention provides a window of opportunity to minimize the social and economic burden incurred by the illness. Many previous studies of effectiveness of early intervention used the historical control approach and are subjected to cohort effects. For example, change of medication pattern over time could potentially lead to differences in outcome. In addition, few studies provide longer-term outcome data of treatment program beyond two years. The optimal length of intervention has not been determined, and many programmes used 12-24 month intervention mainly based on resources available. It is also important to ask whether favorable effects of early intervention could be sustained over time. Further analyses will be done to assess whether EI effects are more pronounced in particular subgroups including DUP, age, sex and diagnosis. The proposed study aims to address these issues by using a randomized controlled design to investigate the longer-term (4 year) outcome of patients with first episode psychosis. The study randomizes 360 patients with first episode psychotic disorders into 3 groups: (1) standard care (outpatient based care with inpatient and community care as required); (2) standard care with 2 years of add-on stage specific case-management (individualized care delivered by designated case managers according to specific protocol); and (3) standard care with 4 years of add-on stage specific case management. The study hypothesis are: (1) both 2 years and 4 years of case management produce better outcomes than standard care alone; (2) 4 years of case management produces better outcome than 2 years of case management.


Recruitment information / eligibility

Status Completed
Enrollment 360
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 26 Years to 55 Years
Eligibility Inclusion Criteria: - DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis nos or delusional disorder - Cantonese-speaking Chinese - Ability to understand the nature of the study and sign informed consent - Capacity to participate in cognitive testing Exclusion Criteria: - Organic Brain disorder - Known history of intellectual disability

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
stage-specific case-management
Stage-specific case-management for psychosis by designated key-workers according to specified protocol

Locations

Country Name City State
China The University of Hong Kong Hong Kong

Sponsors (10)

Lead Sponsor Collaborator
The University of Hong Kong Castle Peak Hospital, Kowloon Hospital, Hong Kong, Kwai Chung Hospital, Hong Kong, North District Hospital, Hong Kong, Queen Elizabeth Hospital, Hong Kong, Queen Mary Hospital, Hong Kong, Shatin Hospital, Tai Po Hospital, United Christian Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functioning (social and occupational) baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Secondary Psychotic symptoms Psychotic symptoms will be assessed using the Positive and Negative Syndrome Scale (PANSS) baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Secondary Psychotic symptoms Psychotic symptoms will be assessed using Scale for the Assessment of Positive Symptoms (SAPS) baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Secondary Psychotic symptoms Psychotic symptoms will be assessed using Scale for the Assessment of Negative Symptoms (SANS). baseline, 6-month, 12-month, 24-month, 36-month, 48-month
Secondary Depressive symptoms Depressive symptoms will be assessed using the Calgary Depression Scale for Schizophrenia (CDSS). baseline, 12-month, 24-month, 36-month, 48-month
Secondary Neurocognitive functioning A battery of neurocognitive tests will be conducted, including Handedness, Trail Making, Wisconsin Card Sorting Test, Semantic Verbal Fluency, Logical Verbal Memory, Visual Patterns Test, Letter Number Span, Monotone Counting, and Soft Neurological Signs. baseline, 12-month, 24-month, 36-month, 48-month
Secondary Health economics baseline, 6-month, 12-month, 24-month, 36-month, 48-month
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00226278 - Safety Study of ORG 34517 for Major Depression With Psychotic Features Phase 2